Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755079 · ClinicalTrials.gov registry record · Phase 2
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
A Phase 2 study of Spinal Cord Injury, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00755079 is a Phase 2 study of Spinal Cord Injury that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 40 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00755079, a Phase 2 study of Spinal Cord Injury, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to determine the effect of administration of the oral beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with cervical (neck) and high thoracic (upper back) spinal cord injury and to compare findings with those obtained in a demographically matched group that will receive placebo. Participation in this study will involve 12 weeks of pharmacological intervention during which participants will be randomized to receive either oral albuterol 4mg twice daily or placebo. All investigators and study participants will be blinded to randomization by our research pharmacy. Participation in the study will require study subjects to come to our lab for the total of 2 visits (at baseline and after week 12), during which a series of tests will be performed to assess their respiratory muscle strength and pulmonary function.
Conditions Studied
Interventions
- DRUG placebo
- DRUG extended release beta-2 adrenergic agonist
Study Locations (1)
New York
- VA Medical Center, Bronx - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755079
The ClinicalTrials.gov registry entry for NCT00755079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (53% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00755079 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00755079 about?
NCT00755079 is a clinical study titled "Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury". The primary purpose of this study is to determine the effect of administration of the oral beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with cervical (neck) and high thoracic (upper back) spinal cord injury and to compare findings with those obtained in a demog...
What is the current status of trial NCT00755079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-04. Estimated completion is 2014-12.
What conditions does trial NCT00755079 study?
This clinical trial studies the following conditions: Spinal Cord Injury.
What interventions are being tested in trial NCT00755079?
The interventions under investigation include: placebo (DRUG), extended release beta-2 adrenergic agonist (DRUG).
Who is sponsoring clinical trial NCT00755079?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00755079 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
RECRUITING · Phase 2
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
RECRUITING · Phase 2
-
Electrical Control of Bladder in Spinal Cord Injury Patients
COMPLETED · Phase 2
-
Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.
COMPLETED · Phase 2
-
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.